
Really desperate for some help -fatigue/depression
#31
Posted 25 February 2007 - 06:20 PM
#32
Posted 25 February 2007 - 10:34 PM
Anyway, I've decided to exercise whether I'm tired or not. Just walking, but it is a start. And I'm focusing on getting a lots of nutrient-rich foods. For example, I'm starting to drink protein shakes (made with protein powder, hemp seeds, kefir, blueberries, spinach and peanut butter) twice a day. I'll avoid wheat and simple carbs. And I will increase my vitamin D for a couple of weeks to see if it helps. I'm also thinking of trying the niacin and B vitamins.
[thumb]
#33
Posted 25 February 2007 - 11:04 PM
I wasn't going to say anything because all the 'experts' would shoot it down but I know an excellent cure for depression. It's the herb salvia divinorum. Do a search on this website and you will find a lot of info. Works like a charm with no negative side effects if used properly. Kids take large doses to have hallucinations which you do not want. That can be avoided, just use the plain leaf not the concentrate and start with small amounts and work up until you find your dose.
J Pharmacol Exp Ther. 2006 Jan;316(1):440-7. Epub 2005 Oct 13.
Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.
Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM.
Department of Psychiatry, McLean Hospital, MRC 217, 115 Mill Street, Belmont, MA 02478. bcarlezon@mclean.harvard.edu
Endogenous opioids seem to play a critical role in the regulation of mood states. For example, there is accumulating evidence that stimulation of kappa-opioid receptors, upon which the endogenous opioid dynorphin acts, can produce depressive-like behaviors in laboratory animals. Here we examined whether systemic administration of salvinorin A (SalvA), a potent and highly selective kappa-opioid agonist, would produce depressive-like effects in the forced swim test (FST) and intracranial self-stimulation (ICSS) test, which are behavioral models often used to study depression in rats. We extracted, isolated, and purified SalvA from Salvia divinorum plant leaves and examined its effects on behavior in the FST and ICSS test across a range of doses (0.125-2.0 mg/kg) after systemic (intraperitoneal) administration. SalvA dose dependently increased immobility in the FST, an effect opposite to that of standard antidepressant drugs. Doses of SalvA that produced these effects in the FST did not affect locomotor activity in an open field. Furthermore, SalvA dose dependently elevated ICSS thresholds, an effect similar to that produced by treatments that cause depressive symptoms in humans. At a dose that caused the depressive-like effects in both the FST and ICSS assays, SalvA decreased extracellular concentrations of dopamine (DA) within the nucleus accumbens (NAc), a critical component of brain reward circuitry, without affecting extracellular concentrations of serotonin (5-HT). These data provide additional support for the hypothesis that stimulation of brain kappa-opioid receptors triggers depressive-like signs in rats and raise the possibility that decreases in extracellular concentrations of DA within the NAc contribute to these effects.
#34
Posted 25 February 2007 - 11:11 PM
Karl R. Hanes, PhD
Journal of Clinical Psychopharmacology 2001;21:634-635
Editors:
Case Report
Ms. G is a 26-year-old woman with a history of depression that has shown no significant periods of remission since adolescence and has been predominated by feelings of worthlessness, lack of interest in social activities, an absence of occupational satisfaction, and inability to find “purpose and meaning” in her life. After first seeking treatment for her depression 5 years ago Ms. G was prescribed sertraline, 50 mg daily, which she self-discontinued after 3 months, reporting no significant benefits. Ms. G then underwent a course of cognitive-behavioural therapy for about 6 months, with some improvement but no definitive resolution of her symptoms. Hamilton Depression Rating Scale (HAM-D 1 ) scores during the 6-month period of cognitive-behavioural therapy were consistently in the moderately depressed range (i.e. 19–21).
During a review consultation some 7 months after discontinuing cognitive-behavioural therapy Ms. G claimed to have found relief from her symptoms of depression with use of the herb salvia divinorum sourced through a mail-order herbal supplier. A HAM-D score of 2 confirmed remission of her symptoms of depression at this time. Ms. G claims that she discovered its antidepressant effects accidentally after smoking the herb and had later developed a method of oral consumption which she claimed maintained its antidepressant effects even after she abstained from using it for up to a week.
Despite being cautioned against use of a herb whose safety profile was unknown, she has continued to use a preparation of salvia divinorum leaves taken as an oral dose of 2–3 leaves (1/2 to 3/4 of a gram of leaf material) three times per week (the leaves are chewed and held in the mouth for 15–30 minutes). During this period she has continued to show a total remission of her symptoms of depression according to HAM-D scores in the range of 0–2 and has maintained this improvement for the last 6 months, showing no signs of relapse and reporting only minimal side effects, such as occasional lightheadedness for up to 1 hour after using the herb.
Ms. G volunteered that she has also benefited from occasional intoxicating oral doses of salvia divinorum, consisting of from 8–16 leaves of the herb (approximately 2 to 4 grams), claiming that this herb had engendered a kind of “psychospiritual” awakening, characterized by the discovery of the depth of her sense of self, greater self-confidence, increased feelings of intuitive wisdom and “connectedness to nature.”
Discussion
Salvia divinorum is a perennial herb of the Labiateae (mint) family native to the Sierra Mazateca region of Oaxaca, Mexico. 2–4 Its main constituents have been identified as the neoclerodane diterpenes Salvinorin A and B 5,6 while trace elements of several other diterpenes have also been detected. 6 The plant has been used in healing ceremonies by the Mazatec Indians of Oaxaca for centuries and for the treatment of such conditions as anaemia, headache, and rheumatism. 7 The psychoactive effects of the main ingredient Salvinorin A in humans were uncovered recently and it has enjoyed some popularity since that time as a legal, short-acting psychedelic, though its psychoactivity varies considerably depending on dosage and method of ingestion. 8
This unique case may be of interest to the psychiatric and psychopharmacological communities in demonstrating the possible therapeutic effects of the unique active components of salvia divinorum in a case of treatmentresistant depression. While the typical dose used by this patient in maintenance management of her depression, consisting of 2–3 leaves, is well below that reported to cause significant intoxication when taken orally, 8 one cannot discount the possibility that some of the benefits derived from salvia divinorum were due to the psychedelic qualities associated with the larger doses of this herb used occasionally by this patient.
While a discussion of these effects is outside the scope of this paper, the value of psychedelic compounds as research tools and their beneficial effects in the amelioration of symptoms of psychiatric conditions is well established. 9–11 Given that the mechanisms of action of the constituents of salvia divinorum remain unknown and the spectrum of psychedelic effects of this herb appears to be unique, 8 it is not inconceivable that research using the active ingredients from this herb may pinpoint a unique mechanism of antidepressant action for these compounds. This, in turn, could lead to methods for the management of depression or of treatment-resistant subtypes of this condition. This possibility is further enhanced by the recent finding using the screening procedure called Novascreen that Salvinorin A did not show significant inhibition of reference target compounds on any of the 42 known bioreceptors tested. 8 We may be dealing with a highly novel agent that has significant research and therapeutic potential in fields such as psychopharmacology, psychiatry and complementary disciplines such as herbal medicine.
Karl R. Hanes, PhD
Cognitive-Behavioural Treatment Centre, Melbourne, Victoria, Australia
References
1. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 1960; 23: 56– 62.
2. Johnson JB. The elements of Mazatec witchcraft. Goteborg Ethnografiska Museum. Ethnologiska Studier 1939; 9: 119– 149.
3. Wasson RG. A new Mexican psychotropic drug from the mint family. Botanical Museum Leaflets. Cambridge, MA: Harvard University 1962; 20: 77– 84.
4. Epling C, Jativa M. A new species of salvia from Mexico. Botanical Museum Leaflets. Cambridge, MA: Harvard University 1962; 20: 75– 76.
5. Ortega A, Blount JF, Manchand PS. Salvinorin, a new transneoclerodane diterpene from salvia divinorum (Labiatae). Journal of the Chemical Society, Perkin Transactions 1:Organic and Bio-Organic Chemistry, 1982;2505–2508.
6. Valdes III, JL Butler WM, Hatfield GM, Paul AG, Koreeda M. Divinorin A, a psychotropic terpenoid and divinorin B from the hallucinogenic mint Salvia divinorum. Journal of Organic Chemistry, 1984; 49: 4716– 4720.
7. Valdes III, JL Diaz JL, Paul AG. Ethnopharmacology of Ska Maria Pastora (Salvia divinorum Epling and Jativa-M). Journal of Ethnopharmacology, 1983; 7: 287– 312.
8. Siebert DJ. Salvia divinorum and Salvinorin A: new pharmacologic findings. Journal of Ethnopharmacology, 1994; 43: 53– 56.
9. Riedlinger TJ, Riedlinger JE. Psychedelic and entactogenic drugs in the treatment of depression. Journal of Psychoactive Drugs, 1994; 26: 41– 55.
10. Henrietta LL, Rapoport JL. Relief of obsessive-compulsive symptoms by LSD and psilocybin. American Journal of Psychiatry, 1987; 144: 1239– 1240.
11. Strassman RJ. Hallucinogenic drugs in psychiatric research and treatment: perspective and prospects. The Journal of Nervous and Mental Disease, 1995; 183: 127– 138.
#35
Posted 26 February 2007 - 12:16 AM
#36
Posted 26 February 2007 - 03:18 AM
#37
Posted 26 February 2007 - 09:28 PM
For food allergy tests you go to a doctor right? I think I may be allergic to milk but I'm not sure yet..
#38
Posted 27 February 2007 - 10:07 PM
#39
Posted 27 February 2007 - 11:59 PM
#40
Posted 28 February 2007 - 12:14 AM
Do you grow this salvia stuff, or buy individual leafs somehow?
You mentioned you were in Canada? If you're in Toronto/GTA, there are lots of sources...I know a greenhouse that sells live plants, and dried leaf is easy to come by. Let me know where you're at!
Don't use the concentrated salvia because it's easier to overdose which can result in brief hallucinations which are like a dream state.
I would of said "frothing state of temporary madness".
#41
Posted 28 February 2007 - 12:17 AM
#42
Posted 28 February 2007 - 07:34 PM
It is not difficult to grow. I am no green thumb and I successfully raised 4 plants from seedlings. Now they are over 2+ feet tall. Just buy some from a greenhouse if you want some nice indoor plants... that you can munch on. :-)
Salvia divinorum is not normally grown from seed nor will you find it in geenhouses. You may be thinking of another species of salvia. They are not all alike and only divinorum has the special properties. Yes, it can be grown but it's difficult for most people which is why I suggested buying some. It requires high humidity to grow and is almost always grown from cuttings. Successful growers often use humidity tents.
#43
Posted 01 March 2007 - 02:21 AM
#44
Posted 20 April 2007 - 12:50 AM
http://www.imminst.o...=0
2 user(s) are reading this topic
0 members, 2 guests, 0 anonymous users